Moderna Inc MRNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 02/26/21 EST

153.30

-1.51 (-0.98%)

Volume

727,440

154.81

+6.43 (+4.33%)

Volume

11,986,795

52 week range

19.31 - 189.26

...

Loading . . .

KEY STATS

Open157.98
Day High159.60
Day Low150.88
Prev Close148.38
52 Week High189.26
52 Week High Date02/08/21
52 Week Low19.31
52 Week Low Date03/13/20
Market Cap61.26B
Shares Out395.71M
10 Day Average Volume8.78M
Dividend-
Dividend Yield-
Beta1.5
1 Year % Change491.78

RATIOS/PROFITABILITY

EPS (TTM)-1.94
P/E (TTM)-79.91
Fwd P/E (NTM)15.80
EBITDA (MRQ)-739.599M
ROE (MRQ)-29.80%
Revenue (MRQ)803.40M
Gross Margin (MRQ)70.05%
Net Margin (MRQ)-92.99%
Debt To Equity (MRQ)3.94%

EVENTS

Earnings Date05/05/2021
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest Moderna Inc News

20 Hours Ago

FDA approves Johnson & Johnson’s single-shot Covid vaccine for emergency use CNBC.com

February 26, 2021

J&J board member says 20 million Covid vaccine doses will be delivered by the end of March CNBC.com

February 26, 2021

FDA panel recommends third vaccine as J&J wins key vote in path to emergency use CNBC.com

February 26, 2021

5 things to know before the stock market opens Friday CNBC.com

February 26, 2021

5 things to know before FDA panel votes on J&J's single-shot Covid vaccine today CNBC.com

Latest MRNA News From Our Partners

20 Hours Ago

Johnson & Johnson COVID-19 vaccine wins FDA's emergency-use approval Seeking Alpha

February 26, 2021

Johnson & Johnson rises as COVID-19 vaccine clears FDA panel vote Seeking Alpha

February 26, 2021

Moderna, Inc. 2020 Q4 - Results - Earnings Call Presentation Seeking Alpha

February 26, 2021

Health Canada authorizes AstraZeneca COVID-19 vaccine Seeking Alpha

February 26, 2021

Moderna: $18 Billion Advance Purchase Orders In FY2021 Barely Moves Share Price, But Still A Buy Seeking Alpha

QUOTE FINDER

Market Movers

Profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...

Noubar Afeyan Ph.D.

Non-Executive Chairman

Stephane Bancel

Chief Executive Officer

Stephen Hoge M.D.

President

David Meline

Chief Financial Officer

Juan Andres

Chief Technology Officer

Lori Henderson J.D.

General Counsel

Address

200 Technology Sq

Cambridge, MA

02139-3578

United States

https://www.modernatx.com/

Moderna Inc MRNA:NASDAQ

KEY STATS

RATIOS/PROFITABILITY

EVENTS

QUOTE FINDER

Related Video

Profile